Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Semaglutide

STEP UP

Novo Nordisk · Phase 3 · Completed · Enrollment 1407

NCT05646706

Y axis: Change in body weight from baseline, %

0-5-10-15-200481216202436486072Semaglutide 7.2 mg, week 72, -18.8%Semaglutide 7.2 mgSemaglutide 2.4 mg, week 72, -15.5%Semaglutide 2.4 mgPlacebo, week 72, -3.9%Placebo

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

  • Semaglutide 7.2 mg: week 72 -18.8%
  • Semaglutide 2.4 mg: week 72 -15.5%
  • Placebo: week 72 -3.9%

One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.